Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Berlin Heals Holding AG Successfully Completes Enrollment in Phase I of the CMIC-III Less Invasive Study
Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected…
Foldax Announces Launch of TRIA Mitral Valve in India
World’s First Approved Polymer Heart Valve Now Available at Select CentersGOA, India--(BUSINESS…
Des pas en alimentation durable mais trop petits pour bien nourrir tout le Qubec
Dévoilement de la politique bioalimentaire 2025-2035 August 22, 2025 12:52 ET  |…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…